Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort
Status:
Completed
Trial end date:
2021-05-28
Target enrollment:
Participant gender:
Summary
The coronavirus disease 2019 (COVID-19) viral pneumonia is now a worldwide pandemic caused by
the Severe acute respiratory virus coronavirus 2 (SARS-CoV-2). The number of cases, and
associated mortality has increased dramatically since the first cases in Wuhan, China in
December 2019 . To date, no specific treatment has been proven to be effective for COVID-19.
Treatment is currently mainly supportive, with in particular mechanical ventilation for the
critically ill patients (6.1% in a series of 1099 cases in China). Novel therapeutic
approaches are in acute need. In this context, the therapeutic potential associated with
convalescent plasma needs to be explored.
The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the
efficacy of convalescent plasma to treat SARS-COV2 infected patients.